SCM
ZNTL icon

Stonepine Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Stonepine Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$630K Sell
269,100
-194,600
-42% -$503K 0.25% 51
2025
Q4 		$626K Buy
463,700
+9,900
+2% +$14.4K 0.46% 46
2025
Q3 		$685K Buy
453,800
+344,790
+316% +$517K 0.56% 34
2025
Q2 		$126K Buy
109,010
+49,010
+82% +$64.6K 0.12% 57
2025
Q1 		$95.4K Buy
+60,000
New +$129K 0.09% 57

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Stonepine Capital Management's ZNTL Position: Q1 2026 in Review

Stonepine Capital Management reduced its Zentalis Pharmaceuticals (ZNTL) stake by 42% in Q1 2026, selling an estimated $503K and leaving 269,100 shares worth $630K. The position accounts for 0.25% of the portfolio, ranked #51.

Stonepine Capital Management first reported a position in ZNTL in Q1 2025 and has held it in 5 quarters since. The position peaked at $685K in Q3 2025. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Stonepine Capital Management held 269,100 shares of Zentalis Pharmaceuticals worth $630K as of Q1 2026.
  • Stonepine Capital Management sold 194,600 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $503K.
  • Zentalis Pharmaceuticals made up 0.25% of Stonepine Capital Management's portfolio in Q1 2026, its #51 holding.
  • Stonepine Capital Management first reported a position in Zentalis Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Stonepine Capital Management's Zentalis Pharmaceuticals position peaked at $685K in Q3 2025.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.